← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
National Marrow Donor Program
Minneapolis, MN
$268,310,503
Total funding
22
Grants
Funding over time
peak $36M · FY2006–25$50M$37.5M$25M$12.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$264,296,515 · 17
NIH$2,508,882 · 3
CDC$1,505,106 · 2
By mechanism
—$264,296,515 · 17
U01$2,149,845 · 1
U58$1,505,106 · 2
UG1$349,037 · 1
R13$10,000 · 1
Investigators at National Marrow Donor Program
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$22,871,053
· FY2024 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$18,000,000
· FY2016 · Department of Defense
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS$18,000,000
· FY2008 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$18,000,000
· FY2014 · Department of Defense
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$18,000,000
· FY2017 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$18,000,000
· FY2020 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$18,000,000
· FY2014 · Department of Defense
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$18,000,000
· FY2023 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCES$17,800,000
· FY2011 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS$17,500,000
· FY2010 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCES$17,500,000
· FY2012 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS$17,500,000
· FY2008 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$16,728,786
· FY2020 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$16,510,000
· FY2021 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$8,417,250
· FY2017 · Department of the Navy
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE$2,881,926
· FY2025 · Department of the Navy
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage$1,076,893
U01 · FY2025 · AI
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage$1,072,951
U01 · FY2024 · AI
DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS$587,500
· FY2010 · Department of the Navy
NATL HLTH ORG STRATEGIES TO PROVIDE INFO ON HEMATOLOGIC CANCERS$330,361
U58 · FY2006 · DP